20 April 2021

Oncode Digital Magazine - April 2021

Welcome to the April edition of our digital magazine. This edition contains interviews with Oncode Investigators, scientific highlights and much more.

Vesna de Jong

This issue, learn all about Oncode Investigator Peter ten Dijke’s work on the TGF-β growth factor, with the ultimate goal of developing novel cancer treatments (Story section). Read further for insights into the challenges of turning a drug target or a biomarker into a clinical product, in the Dialogue between Oncode Investigator Rebekka Schneider and Jan Groen, CEO of Intravacc and member of the Investment Advisory Committee of the Oncode Bridge Fund. And don’t forget the #Eureka section for the latest updates, and the Portrait section - for your chance to get to know Oncode Investigator Anne Rios better.

Click here to open the magazine

Other News

Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboud University) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
200708 t1 5 Nor pn20 replated Day3 d0 No GF 0001 TRANS
'Live' measurements of cell signals show need for combination therapy in colorectal cancer
The team of Oncode Investigator Hugo Snippert (UMC Utrecht) has succeeded in using organoid technology to monitor live how a colon tumor responds to a combination therapy. The results appear today, April 1st, in the leading journal Nature Cell Biology.